The triglyceride-glucose index, ventricular arrhythmias and major cardiovascular events in patients at high risk of sudden cardiac death.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Death, Sudden, Cardiac*/epidemiology ; Death, Sudden, Cardiac*/etiology ; Triglycerides*/blood ; Blood Glucose*/metabolism ; Tachycardia, Ventricular*/blood ; Tachycardia, Ventricular*/diagnosis ; Tachycardia, Ventricular*/mortality ; Ventricular Fibrillation*/diagnosis ; Ventricular Fibrillation*/blood ; Ventricular Fibrillation*/mortality ; Ventricular Fibrillation*/therapy ; Biomarkers*/blood; Humans ; Female ; Middle Aged ; Male ; Aged ; Risk Assessment ; Risk Factors ; Time Factors ; China/epidemiology ; Defibrillators, Implantable ; Electric Countershock/instrumentation ; Electric Countershock/mortality ; Electric Countershock/adverse effects ; Retrospective Studies ; Prognosis ; Treatment Outcome ; Adult ; Patient Readmission

Background: The association between the triglyceride-glucose (TyG) index and ventricular arrhythmias (VAs) is unclear. This study aimed to investigate the relationship between the TyG index, VAs, and major cardiovascular events in patients at high risk of sudden cardiac death (SCD).
Methods: We enrolled 1046 patients at high risk of SCD with an indication for implantable cardioverter-defibrillator (ICD) implantation at the Chinese National Center for Cardiovascular Diseases. The primary outcome was VAs, defined as sustained ventricular tachycardia and ventricular fibrillation documented by the ICD. The secondary outcomes were cardiac mortality, heart transplantation, and rehospitalization for heart failure.
Results: The mean (± SD) age was 59.6 ± 14.0 years old, and 25.7% were female. During the mean follow-up of 36.1 months, 342 (32.7%) patients had VAs, and 185 (17.7%) patients had major cardiovascular events. The mean fasting glucose and triglyceride levels were 111.9 ± 42.7 mg/dL and 140.0 ± 95.4 mg/L, respectively, with a TyG index range of 6.96-11.8. In the Fine-Gray subdistribution hazard model analysis, an increase in the TyG index was associated with a significant increase in the VAs (per 1 TyG index, hazard ratio [HR] 2.95; 95% confidence interval [CI], 2.29-3.80) and secondary outcome (HR 2.84; 95% CI 1.86-4.34). When stratified into tertiles, the risk of VAs was significantly higher in the highest tertile (HR 4.08; 95% CI, 2.81-5.92) than in the lowest tertile. Analysis of the secondary outcome revealed similar findings (HR 3.18; 95% CI, 1.73-5.85).
Conclusions: In our cohort, the pre-operational TyG index is significantly associated with VAs and major cardiovascular events for patients with high risk of SCD.
(© 2024. The Author(s).)

Nutrients. 2021 Dec 31;14(1):. (PMID: 35011056)
Cardiovasc Diabetol. 2022 May 31;21(1):88. (PMID: 35641978)
Cardiovasc Diabetol. 2023 Jul 6;22(1):170. (PMID: 37415168)
Sci Rep. 2022 Jul 19;12(1):12307. (PMID: 35854061)
Eur Heart J. 2017 Oct 21;38(40):3017-3025. (PMID: 28662567)
Eur J Med Res. 2024 Feb 12;29(1):118. (PMID: 38347644)
World J Diabetes. 2023 Aug 15;14(8):1163-1177. (PMID: 37664481)
Cardiovasc Diabetol. 2023 Aug 31;22(1):232. (PMID: 37653418)
Diabetes Metab. 2022 Nov;48(6):101390. (PMID: 36170946)
J Am Heart Assoc. 2018 Jul 7;7(14):. (PMID: 29982228)
Cardiovasc Diabetol. 2023 Jan 6;22(1):2. (PMID: 36609319)
Cardiovasc Diabetol. 2018 Oct 19;17(1):136. (PMID: 30340589)
Am J Cardiol. 2011 Jul 1;108(1):56-62. (PMID: 21529739)
Lancet. 2023 Sep 9;402(10405):883-936. (PMID: 37647926)
J Am Coll Cardiol. 2022 Apr 26;79(16):1579-1590. (PMID: 35450575)
Diabetes Res Clin Pract. 2023 May;199:110629. (PMID: 36948422)
Cardiovasc Diabetol. 2023 May 13;22(1):111. (PMID: 37179288)
Nutr Diabetes. 2024 Jun 6;14(1):39. (PMID: 38844442)
Cardiovasc Diabetol. 2022 Jul 1;21(1):124. (PMID: 35778731)
Circulation. 2021 May 25;143(21):e984-e1010. (PMID: 33882682)
Diabetes Metab Syndr. 2022 Aug;16(8):102581. (PMID: 35939943)
Eur J Prev Cardiol. 2016 Mar;23(5):511-7. (PMID: 26069245)
Cardiovasc Diabetol. 2022 May 6;21(1):68. (PMID: 35524263)
Cardiovasc Diabetol. 2023 May 18;22(1):118. (PMID: 37208737)
J Am Heart Assoc. 2016 Feb 19;5(2):. (PMID: 26896476)
Am J Med. 2018 May;131(5):532-539.e5. (PMID: 29273191)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Int J Endocrinol. 2020 Mar 10;2020:4678526. (PMID: 32256572)
Cardiovasc Diabetol. 2024 Jun 28;23(1):224. (PMID: 38943159)
Diabetes Metab J. 2021 Mar;45(2):146-157. (PMID: 33813813)
J Mol Cell Cardiol. 2014 Apr;69:24-31. (PMID: 24412579)
Heart Rhythm. 2016 Aug;13(8):1699-706. (PMID: 27154230)
Nutr Diabetes. 2024 Sep 28;14(1):80. (PMID: 39341836)
Cardiovasc Diabetol. 2023 Sep 7;22(1):244. (PMID: 37679763)
J Diabetes. 2015 Mar;7(2):250-259. (PMID: 24796789)
Eur Heart J. 2022 Oct 21;43(40):3997-4126. (PMID: 36017572)

82070351 National Natural Science Foundation of China; 2022-I2M-C&T-B-049 CAMS Innovation Fund for Medical Sciences

Keywords: Implantable cardioverter–defibrillator; Major cardiovascular events; Sudden cardiac death; Triglyceride-glucose index; Ventricular arrhythmias

0 (Triglycerides)
0 (Blood Glucose)
0 (Biomarkers)

Date Created: 20241029 Date Completed: 20241029 Latest Revision: 20250113

20250113

PMC11514788

10.1186/s12933-024-02484-9

39468566